Get the Stockscreener App
86.99
0.35%
-0.42
Praxis Precision Medicines Inc stock is traded at $86.99, with a volume of 204.01K.
It is down -0.35% in the last 24 hours and up +12.36% over the past month.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.
See More
Previous Close:
$87.41
Open:
$87.16
24h Volume:
204.01K
Relative Volume:
0.58
Market Cap:
$1.63B
Revenue:
$1.77M
Net Income/Loss:
$-123.74M
P/E Ratio:
-9.4864
EPS:
-9.17
Net Cash Flow:
$-95.21M
1W Performance:
+13.79%
1M Performance:
+12.36%
6M Performance:
+67.41%
1Y Performance:
+97.52%
1-Day Range:
$85.75
$88.40
1-Week Range:
$74.06
$90.33
52-Week Range:
$33.01
$90.33
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Name
Praxis Precision Medicines Inc
Sector
Industry
Phone
617-300-8460
Address
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
87.21 | 1.63B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.57 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.57 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
653.51 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.50 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.28 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-05-24 | Initiated | Oppenheimer | Outperform |
| Jun-24-24 | Initiated | Needham | Buy |
| Jun-18-24 | Initiated | Guggenheim | Buy |
| May-01-24 | Initiated | Robert W. Baird | Outperform |
| Sep-19-23 | Initiated | Truist | Buy |
| Jun-06-22 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Aug-26-21 | Initiated | BofA Securities | Buy |
| Apr-26-21 | Initiated | William Blair | Outperform |
| Nov-11-20 | Initiated | Wedbush | Outperform |
| Nov-10-20 | Initiated | Cowen | Outperform |
| Nov-10-20 | Initiated | Evercore ISI | Outperform |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Praxis Precision Medicines Inc Stock (PRAX) Latest News
China Universal Asset Management Co. Ltd. Makes New Investment in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Praxis Precision Medicines (NASDAQ:PRAX) Trading 5.8% HigherStill a Buy? - MarketBeat
Praxis Precision Medicines (NASDAQ:PRAX) Hits New 52-Week HighStill a Buy? - MarketBeat
Morgan Stanley's Strategic Acquisition of Praxis Precision Medic - GuruFocus.com
Should You Invest in Nasdaq Inc (NDAQ) Now? - The News Heater
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Praxis Precision Medicines to Present at Two February Investor Conferences - The Manila Times
CNS Drug Developer Praxis Lines Up Exclusive Investor Access at Guggenheim & Oppenheimer Events - StockTitan
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives $149.11 Average Price Target from Brokerages - MarketBeat
Learn to Evaluate (PRAX) using the Charts - Stock Traders Daily
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Purchased by JPMorgan Chase & Co. - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Praxis Precision Medicines (PRAX) Stock Price, News & Analysis - MarketBeat
Jefferies maintains Praxis stock with $305 target, bullish on catalysts - MSN
Noteworthy Wednesday Option Activity: PRAX, ORCL, SOC - Nasdaq
Jefferies maintains Praxis stock with $305 target, bullish on catalysts By Investing.com - Investing.com South Africa
Truist Financial Issues Positive Forecast for Praxis Precision Medicines (NASDAQ:PRAX) Stock Price - Defense World
Praxis Precision Medicines (NASDAQ:PRAX) Shares Up 8.5% Following Analyst Upgrade - Defense World
Expert Outlook: Praxis Precision Medicine Through The Eyes Of 5 Analysts - Benzinga
Praxis Precision Medicines (NASDAQ:PRAX) Trading Up 8.5% Following Analyst Upgrade - MarketBeat
Truist raises Praxis stock target to $175 on study optimism - MSN
Truist raises Praxis stock target to $175 on study optimism By Investing.com - Investing.com Australia
Praxis Precision Medicines (NASDAQ:PRAX) Given New $175.00 Price Target at Truist Financial - MarketBeat
Ellsworth Advisors LLC Takes $627,000 Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Short Interest Update - MarketBeat
Trend Tracker for (PRAX) - Stock Traders Daily
Assenagon Asset Management S.A. Has $43.03 Million Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Praxis Precision Medicines Unveils Ambitious 2025 Strategy: 4 Pivotal Trial Readouts, $470M Cash Runway - StockTitan
Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities - The Bakersfield Californian
Praxis Precision Medicines (NASDAQ:PRAX) Shares Down 8.9%Here's Why - MarketBeat
(PRAX) Trading Report - Stock Traders Daily
Praxis Precision Medicines to Present at J.P. Morgan Healthcare Conference - The Manila Times
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Long Term Trading Analysis for (PRAX) - Stock Traders Daily
Geode Capital Management LLC Has $22.95 Million Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Bought by Barclays PLC - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Acquired by Barclays PLC - MarketBeat
Praxis Precision Medicines: Multiple Potential Drivers (NASDAQ:PRAX) - Seeking Alpha
Praxis Precision Medicines Inc (NASDAQ: PRAX) Stock Sentiment: What’s Wall Street Saying? - Stocks Register
Franklin Resources Inc. Grows Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
State Street Corp Has $45.44 Million Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $913,000 Stock Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
(PRAX) Technical Data - Stock Traders Daily
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine - The Bakersfield Californian
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome - GlobeNewswire
Praxis Precision Medicines Secures Key FDA Designation for Promising Epilepsy Drug Relutrigine - StockTitan
Praxis Precision Medicines (NASDAQ:PRAX) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Wellington Management Group LLP Buys 168,394 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Praxis Precision Medicines’ (PRAX) Buy Rating Reiterated at HC Wainwright - Defense World
Praxis Precision Medicines Inc Stock (PRAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Praxis Precision Medicines Inc Stock (PRAX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Nemiroff Alex | General Counsel and Secretary |
Nov 14 '24 |
Sale |
80.20 |
8,239 |
660,827 |
10,301 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 14 '24 |
Option Exercise |
56.94 |
4,374 |
249,056 |
10,801 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 14 '24 |
Sale |
81.78 |
5,188 |
424,318 |
5,613 |
0.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):